Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Cash from Investing Activities: 2009-2025

Historic Cash from Investing Activities for Amicus Therapeutics (FOLD) over the last 14 years, with Sep 2025 value amounting to -$1.3 million.

  • Amicus Therapeutics' Cash from Investing Activities fell 103.79% to -$1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$60.3 million, marking a year-over-year decrease of 1362.55%. This contributed to the annual value of -$560,000 for FY2024, which is 100.57% down from last year.
  • Latest data reveals that Amicus Therapeutics reported Cash from Investing Activities of -$1.3 million as of Q3 2025, which was up 77.52% from -$5.8 million recorded in Q2 2025.
  • In the past 5 years, Amicus Therapeutics' Cash from Investing Activities ranged from a high of $86.6 million in Q1 2021 and a low of -$68.1 million during Q4 2021.
  • In the last 3 years, Amicus Therapeutics' Cash from Investing Activities had a median value of -$1.3 million in 2025 and averaged $5.2 million.
  • In the last 5 years, Amicus Therapeutics' Cash from Investing Activities skyrocketed by 122.44% in 2021 and then slumped by 536.00% in 2025.
  • Over the past 5 years, Amicus Therapeutics' Cash from Investing Activities (Quarterly) stood at -$68.1 million in 2021, then increased by 2.03% to -$66.7 million in 2022, then soared by 64.08% to -$24.0 million in 2023, then climbed by 14.88% to -$20.4 million in 2024, then slumped by 103.79% to -$1.3 million in 2025.
  • Its last three reported values are -$1.3 million in Q3 2025, -$5.8 million for Q2 2025, and -$32.9 million during Q1 2025.